MET: A New Promising Biomarker in Non-Small-Cell Lung Carcinoma

References

• Siegel R , MaJ , ZouZ , JemalA . Cancer statistics, 2014 . CA Cancer J. Clin.64 ( 1 ), 9 – 29 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Edge S , ByrdDR , ComptonCC , FritzAG , GreeneFL , TrottiA . AJCC Cancer Staging Manual. (7th Edition).649 ( 2010 ).
   Google Scholar
• Herbst RS1 , HeymachJV , LippmanSM . Lung cancer . N. Engl. J. Med.359 ( 13 ), 1367 – 1380 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Molina JR , YangP , CassiviSD , SchildSE , AdjeiAA . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship . Mayo Clin. Proc.83 ( 5 ), 584 – 594 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kelly K , CrowleyJ , BunnPA , Jret al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial . J. Clin. Oncol.19 ( 13 ), 3210 – 3218 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV , De MarinisF , RinaldiMet al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer . J. Clin. Oncol.20 ( 21 ), 4285 – 4291 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Schiller JH , HarringtonD , BelaniCPet al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N. Engl. J. Med.346 ( 2 ), 92 – 98 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Fossella F , PereiraJR , Von PawelJet al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group . J. Clin. Oncol.21 ( 16 ), 3016 – 3024 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Han SW , KimTY , HwangPGet al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib . J. Clin. Oncol.23 ( 11 ), 2493 – 2501 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , KosakaT , EndohHet al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence . J. Clin. Oncol.23 ( 11 ), 2513 – 2520 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Takano T , OheY , SakamotoHet al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer . J. Clin. Oncol.23 ( 28 ), 6829 – 6837 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Taron M , IchinoseY , RosellRet al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas . Clin. Cancer Res.11 ( 16 ), 5878 – 5885 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Costa DB , KobayashiS , TenenDG , HubermanMS . Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers . Lung Cancer58 ( 1 ), 95 – 103 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Pao W , GirardN . New driver mutations in non-small-cell lung cancer . Lancet Oncol.12 ( 2 ), 175 – 180 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rosell R , MoranT , QueraltCet al. Screening for epidermal growth factor receptor mutations in lung cancer . N. Engl. J. Med.361 ( 10 ), 958 – 967 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Inoue A , KobayashiK , MaemondoMet al. Updated overall survival results from a randomized Phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) . Ann. Oncol.24 ( 1 ), 54 – 59 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS , YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial . Lancet Oncol.11 ( 2 ), 121 – 128 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zhou C , WuYL , ChenGet al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study . Lancet Oncol.12 ( 8 ), 735 – 742 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jackman D , PaoW , RielyGJet al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer . J. Clin. Oncol.28 ( 2 ), 357 – 360 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Rosell R , CarcerenyE , GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial . Lancet Oncol.13 ( 3 ), 239 – 246 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Thomson S , BuckE , PettiFet al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition . Cancer Res.65 ( 20 ), 9455 – 9462 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Tang JM , HeQY , GuoRX , ChangXJ . Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis . Lung Cancer51 ( 2 ), 181 – 191 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Pao W , WangTY , RielyGJet al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib . PLoS Med.2 ( 1 ), e17 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Massarelli E , Varella-GarciaM , TangXet al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer . Clin. Cancer Res.13 ( 10 ), 2890 – 2896 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lim WT , ZhangWH , MillerCRet al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer . Oncol. Rep.17 ( 4 ), 853 – 857 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Arcila ME , ChaftJE , NafaKet al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas . Clin. Cancer Res.18 ( 18 ), 4910 – 4918 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ohashi K , SequistLV , ArcilaMEet al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 . Proc. Natl Acad. Sci USA109 ( 31 ), E2127 – E2133 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Engelman JA , ZejnullahuK , MitsudomiTet al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling . Science316 ( 5827 ), 1039 – 1043 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Yano S , WangW , LiQet al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations . Cancer Res.68 ( 22 ), 9479 – 9487 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Byers LA , DiaoL , WangJet al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance . Clin. Cancer Res.19 ( 1 ), 279 – 290 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wu F , LiJ , JangC , WangJ , XiongJ . The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma . Int. J. Clin. Exp. Pathol.7 ( 10 ), 6653 – 6661 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhang Z , LeeJC , LinLet al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer . Nat. Genet.44 ( 8 ), 852 – 860 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Appleman LJ . MET signaling pathway: a rational target for cancer therapy . J. Clin. Oncol.29 ( 36 ), 4837 – 4838 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bean J , BrennanC , ShihJYet al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib . Proc. Natl Acad. Sci USA104 ( 52 ), 20932 – 20937 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ding L , GetzG , WheelerDAet al. Somatic mutations affect key pathways in lung adenocarcinoma . Nature455 ( 7216 ), 1069 – 1075 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S , KantetiR , Duke-CohanJSet al. Ethnic differences and functional analysis of MET mutations in lung cancer . Clin. Cancer Res.15 ( 18 ), 5714 – 5723 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ma PC , JagadeeswaranR , JagadeeshSet al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer . Cancer Res.65 ( 4 ), 1479 – 1488 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Cooper CS , ParkM , BlairDGet al. Molecular cloning of a new transforming gene from a chemically transformed human cell line . Nature311 ( 5981 ), 29 – 33 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Duh FM , SchererSW , TsuiLC , LermanMI , ZbarB , SchmidtL . Gene structure of the human MET proto-oncogene . Oncogene15 ( 13 ), 1583 – 1586 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Liu Y . The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization . Gene215 ( 1 ), 159 – 169 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Comoglio PM , BoccaccioC . The HGF receptor family: unconventional signal transducers for invasive cell growth . Genes Cells1 ( 4 ), 347 – 354 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Maestrini E , TamagnoneL , LongatiPet al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor . Proc. Natl Acad. Sci USA93 ( 2 ), 674 – 678 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Cipriani NA , AbidoyeOO , VokesE , SalgiaR . MET as a target for treatment of chest tumors . Lung Cancer63 ( 2 ), 169 – 179 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ma PC , MaulikG , ChristensenJ , SalgiaR . c-Met: structure, functions and potential for therapeutic inhibition . Cancer Metastasis Rev.22 ( 4 ), 309 – 325 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Stellrecht CM , GandhiV . MET receptor tyrosine kinase as a therapeutic anticancer target . Cancer Lett.280 ( 1 ), 1 – 14 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gherardi E , BirchmeierW , BirchmeierC , Vande WoudeG . Targeting MET in cancer: rationale and progress . Nat. Rev. Cancer12 ( 2 ), 89 – 103 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Abella JV , PeschardP , NaujokasMAet al. Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation . Mol. Cell Biol.25 ( 21 ), 9632 – 9645 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Gandino L , LongatiP , MedicoE , PratM , ComoglioPM . Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase . J. Biol. Chem.269 ( 3 ), 1815 – 1820 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Petrelli A , GilestroGF , LanzardoS , ComoglioPM , MigoneN , GiordanoS . The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met . Nature416 ( 6877 ), 187 – 190 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Soubeyran P , KowanetzK , SzymkiewiczI , LangdonWY , DikicI . Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors . Nature416 ( 6877 ), 183 – 187 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Fournier TM , KamikuraD , TengK , ParkM . Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase . J. Biol. Chem.271 ( 36 ), 22211 – 22217 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Weidner KM , SachsM , RiethmacherD , BirchmeierW . Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells . Proc. Natl Acad. Sci USA92 ( 7 ), 2597 – 2601 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Rodrigues GA , ParkM . Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase . Oncogene9 ( 7 ), 2019 – 2027 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Trusolino L , BertottiA , ComoglioPM . MET signalling: principles and functions in development, organ regeneration and cancer . Nat. Rev. Mol. Cell Biol.11 ( 12 ), 834 – 848 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Furge KA , ZhangYW , Vande WoudeGF . Met receptor tyrosine kinase: enhanced signaling through adapter proteins . Oncogene19 ( 49 ), 5582 – 5589 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ponzetto C , BardelliA , ZhenZet al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family . Cell77 ( 2 ), 261 – 271 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Stella MC , ComoglioPM . HGF: a multifunctional growth factor controlling cell scattering . Int. J. Biochem. Cell Biol.31 ( 12 ), 1357 – 1362 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Gherardi E , SandinS , PetoukhovMVet al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling . Proc. Natl Acad. Sci USA103 ( 11 ), 4046 – 4051 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Maina F , CasagrandaF , AuderoEet al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development . Cell87 ( 3 ), 531 – 542 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Zanetti A , StoppacciaroA , MarzulloAet al. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid . J. Pathol.186 ( 3 ), 287 – 291 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Sonnenberg E , MeyerD , WeidnerKM , BirchmeierC . Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development . J. Cell Biol.123 ( 1 ), 223 – 235 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Stamos J , LazarusRA , YaoX , KirchhoferD , WiesmannC . Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor . EMBO J.23 ( 12 ), 2325 – 2335 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Gelsomino F , FacchinettiF , HaspingerERet al. Targeting the MET gene for the treatment of non-small-cell lung cancer . Crit. Rev. Oncol. Hematol.89 ( 2 ), 284 – 299 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Andermarcher E , SuraniMA , GherardiE . Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis . Dev. Genet.18 ( 3 ), 254 – 266 ( 1996 ).
   PubMedGoogle Scholar
• Birchmeier C , GherardiE . Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase . Trends Cell Biol.8 ( 10 ), 404 – 410 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Bladt F , RiethmacherD , IsenmannS , AguzziA , BirchmeierC . Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud . Nature376 ( 6543 ), 768 – 771 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Bussolino F , Di RenzoMF , ZicheMet al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth . J. Cell Biol.119 ( 3 ), 629 – 641 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Gentile A , TrusolinoL , ComoglioPM . The Met tyrosine kinase receptor in development and cancer . Cancer Metastasis Rev.27 ( 1 ), 85 – 94 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Huh C-G , FactorVM , SánchezA , UchidaK , ConnerEA , ThorgeirssonSS . Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair . Proc. Natl Acad. Sci USA101 ( 13 ), 4477 – 4482 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Knudsen BS , Vande WoudeG . Showering c-MET-dependent cancers with drugs . Curr. Opin. Genet. Dev.18 ( 1 ), 87 – 96 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Schmidt C , BladtF , GoedeckeSet al. Scatter factor/hepatocyte growth factor is essential for liver development . Nature373 ( 6516 ), 699 – 702 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Streit A , SternCD , TheryCet al. A role for HGF/SF in neural induction and its expression in Hensen’s node during gastrulation . Development121 ( 3 ), 813 – 824 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Takayama H , La RochelleWJ , AnverM , BockmanDE , MerlinoG . Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development . Proc. Natl Acad. Sci. USA93 ( 12 ), 5866 – 5871 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Uehara Y , MinowaO , MoriCet al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor . Nature373 ( 6516 ), 702 – 705 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Van Der Voort R , TaherTE , DerksenPW , SpaargarenM , Van Der NeutR , PalsST . The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation . Adv. Cancer Res.79 , 39 – 90 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Van Der Voort R , TaherTE , KeehnenRM , SmitL , GroeninkM , PalsST . Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway . J. Exp. Med.185 ( 12 ), 2121 – 2131 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Ikehara S . Role of hepatocyte growth factor in hemopoiesis . Leuk. Lymphoma23 ( 3–4 ), 297 – 303 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Birchmeier C , BirchmeierW , GherardiE , Vande WoudeGF . Met, metastasis, motility and more . Nat. Rev. Mol. Cell Biol.4 ( 12 ), 915 – 925 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Boccaccio C , AndoM , TamagnoneLet al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway . Nature391 ( 6664 ), 285 – 288 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Fixman ED , FournierTM , KamikuraDM , NaujokasMA , ParkM . Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein . J. Biol. Chem.271 ( 22 ), 13116 – 13122 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Fixman ED , NaujokasMA , RodriguesGA , MoranMF , ParkM . Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus . Oncogene10 ( 2 ), 237 – 249 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Maroun CR , Holgado-MadrugaM , RoyalIet al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase . Mol. Cell Biol.19 ( 3 ), 1784 – 1799 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Ponzetto C , BardelliA , MainaFet al. A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor . Mol. Cell Biol.13 ( 8 ), 4600 – 4608 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Stefan M , KochA , ManciniAet al. Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis . J. Biol. Chem.276 ( 5 ), 3017 – 3023 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Lock LS , FrigaultMM , SaucierC , ParkM . Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain . J. Biol. Chem.278 ( 32 ), 30083 – 30090 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Lock LS , RoyalI , NaujokasMA , ParkM . Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases . J. Biol. Chem.275 ( 40 ), 31536 – 31545 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Holgado-Madruga M , EmletDR , MoscatelloDK , GodwinAK , WongAJ . A Grb2-associated docking protein in EGF- and insulin-receptor signalling . Nature379 ( 6565 ), 560 – 564 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Lamorte L , RodriguesS , NaujokasM , ParkM . Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program . J. Biol. Chem.277 ( 40 ), 37904 – 37911 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Maroun CR , NaujokasMA , Holgado-MadrugaM , WongAJ , ParkM . The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase . Mol. Cell Biol.20 ( 22 ), 8513 – 8525 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Schaeper U , GehringNH , FuchsKP , SachsM , KempkesB , BirchmeierW . Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses . J. Cell Biol.149 ( 7 ), 1419 – 1432 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Weidner KM , Di CesareS , SachsM , BrinkmannV , BehrensJ , BirchmeierW . Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis . Nature384 ( 6605 ), 173 – 176 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Fournier TM , LamorteL , MarounCRet al. Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion . Mol. Biol. Cell.11 ( 10 ), 3397 – 3410 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Day RM , CioceV , BreckenridgeD , CastagninoP , BottaroDP . Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis . Oncogene18 ( 22 ), 3399 – 3406 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Fan S , MaYX , WangJAet al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase . Oncogene19 ( 18 ), 2212 – 2223 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Nakanishi K , FujimotoJ , UekiTet al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase . Clin. Exp. Metastasis17 ( 6 ), 507 – 514 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Potempa S , RidleyAJ . Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly . Mol. Biol. Cell.9 ( 8 ), 2185 – 2200 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Xiao GH , JeffersM , BellacosaA , MitsuuchiY , Vande WoudeGF , TestaJR . Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways . Proc. Natl Acad. Sci. USA98 ( 1 ), 247 – 252 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Chen HC , ChanPC , TangMJ , ChengCH , ChangTJ . Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation . J. Biol. Chem.273 ( 40 ), 25777 – 25782 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Gual P , GiordanoS , WilliamsTA , RocchiS , Van ObberghenE , ComoglioPM . Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis . Oncogene19 ( 12 ), 1509 – 1518 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Kodama A , TakaishiK , NakanoK , NishiokaH , TakaiY . Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells . Oncogene18 ( 27 ), 3996 – 4006 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Lai JF , KaoSC , JiangST , TangMJ , ChanPC , ChenHC . Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells . J. Biol. Chem.275 ( 11 ), 7474 – 7480 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Lamorte L , KamikuraDM , ParkM . A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein . Oncogene19 ( 52 ), 5973 – 5981 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Lamorte L , RodriguesS , SangwanV , TurnerCE , ParkM . Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts . Mol. Biol. Cell.14 ( 7 ), 2818 – 2831 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ridley AJ , ComoglioPM , HallA . Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells . Mol. Cell Biol.15 ( 2 ), 1110 – 1122 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Royal I , Lamarche-VaneN , LamorteL , KaibuchiK , ParkM . Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation . Mol. Biol. Cell.11 ( 5 ), 1709 – 1725 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Sakkab D , LewitzkyM , PosernGet al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL . J. Biol. Chem.275 ( 15 ), 10772 – 10778 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Hammond DE , UrbeS , Vande WoudeGF , ClagueMJ . Down-regulation of MET, the receptor for hepatocyte growth factor . Oncogene20 ( 22 ), 2761 – 2770 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Peschard P , ParkM . Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases . Cancer Cell3 ( 6 ), 519 – 523 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Machide M , HashigasakoA , MatsumotoK , NakamuraT . Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase . J. Biol. Chem.281 ( 13 ), 8765 – 8772 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Palka HL , ParkM , TonksNK . Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1 . J. Biol. Chem.278 ( 8 ), 5728 – 5735 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Sangwan V , PaliourasGN , AbellaJVet al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase . J. Biol. Chem.283 ( 49 ), 34374 – 34383 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gandino L , Di RenzoMF , GiordanoS , BussolinoF , ComoglioPM . Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein . Oncogene5 ( 5 ), 721 – 725 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Gandino L , MunaronL , NaldiniL , FerraciniR , MagniM , ComoglioPM . Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene . J. Biol. Chem.266 ( 24 ), 16098 – 16104 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Liu X , NewtonRC , ScherlePA . Developing c-MET pathway inhibitors for cancer therapy: progress and challenges . Trends Mol Med.16 ( 1 ), 37 – 45 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Turner FE , BroadS , KhanimFLet al. Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes . J. Biol. Chem.281 ( 30 ), 21321 – 21331 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mejlvang J , KriajevskaM , VandewalleCet al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition . Mol. Biol. Cell.18 ( 11 ), 4615 – 4624 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Fearon ER , VogelsteinB . A genetic model for colorectal tumorigenesis . Cell61 ( 5 ), 759 – 767 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA . The hallmarks of cancer . Cell100 ( 1 ), 57 – 70 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Hu B , GuoP , Bar-JosephIet al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway . Oncogene26 ( 38 ), 5577 – 5586 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tamagnone L , ArtigianiS , ChenHet al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates . Cell99 ( 1 ), 71 – 80 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Birchmeier W , BrinkmannV , NiemannCet al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells . Ciba Found. Symp.212 , 230 – 240 ; discussion 240–236 ( 1997 ).
   PubMedGoogle Scholar
• Birchmeier W , WeidnerKM , BehrensJ . Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells . J. Cell Sci. Suppl.17 , 159 – 164 ( 1993 ).
   PubMedGoogle Scholar
• Rodrigues GA , ParkM , SchlessingerJ . Activation of the JNK pathway is essential for transformation by the Met oncogene . EMBO J.16 ( 10 ), 2634 – 2645 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Royal I , ParkM . Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase . J. Biol. Chem.270 ( 46 ), 27780 – 27787 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Schildhaus HU , SchultheisAM , RuschoffJet al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung . Clin. Cancer Res.21 ( 4 ), 907 – 915 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lutterbach B , ZengQ , DavisLJet al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival . Cancer Res.67 ( 5 ), 2081 – 2088 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Arcila ME , OxnardGR , NafaKet al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay . Clin. Cancer Res.17 ( 5 ), 1169 – 1180 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sequist LV , WaltmanBA , Dias-SantagataDet al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors . Sci. Transl. Med.3 ( 75 ), 75ra26 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Arteaga CL . HER3 and mutant EGFR meet MET . Nat. Med.13 ( 6 ), 675 – 677 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F , JannePA , SkokanMet al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients . Ann. Oncol.20 ( 2 ), 298 – 304 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Jiang W , HiscoxS , MatsumotoK , NakamuraT . Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer . Crit. Rev. Oncol. Hematol.29 ( 3 ), 209 – 248 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Chen JT , LinTS , ChowKCet al. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells . Am. J. Respir. Cell Mol. Biol.34 ( 3 ), 264 – 273 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kosaka T , YamakiE , MogiA , KuwanoH . Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer . J. Biomed. Biotechnol.2011 , 165214 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sequist LV , Von PawelJ , GarmeyEGet al. Randomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer . J. Clin. Oncol.29 ( 24 ), 3307 – 3315 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Spigel DR , ErvinTJ , RamlauRAet al. Randomized Phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer . J. Clin. Oncol.31 ( 32 ), 4105 – 4114 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Schmidt L , DuhFM , ChenFet al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas . Nat. Genet.16 ( 1 ), 68 – 73 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Schmidt L , JunkerK , NakaigawaNet al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas . Oncogene18 ( 14 ), 2343 – 2350 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Lee JH , HanSU , ChoHet al. A novel germ line juxtamembrane Met mutation in human gastric cancer . Oncogene19 ( 43 ), 4947 – 4953 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ludovini V , BianconiF , PistolaLet al. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations . Cancer Chemother. Pharmacol.69 ( 5 ), 1289 – 1299 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ma PC , TretiakovaMS , MackinnonACet al. Expression and mutational analysis of MET in human solid cancers . Genes Chromosomes Cancer47 ( 12 ), 1025 – 1037 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Park WS , DongSM , KimSYet al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas . Cancer Res.59 ( 2 ), 307 – 310 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Seiwert TY , JagadeeswaranR , FaoroLet al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma . Cancer Res.69 ( 7 ), 3021 – 3031 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zeng ZS , WeiserMR , KuntzEet al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases . Cancer Lett.265 ( 2 ), 258 – 269 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kong-Beltran M , SeshagiriS , ZhaJet al. Somatic mutations lead to an oncogenic deletion of met in lung cancer . Cancer Res.66 ( 1 ), 283 – 289 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lorenzato A , OliveroM , PatanèSet al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion . Cancer Res.62 , 7025 – 7030 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Hellerstedt BA , EdelmanG , VogelzangNjet al. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a Phase II randomized discontinuation trial (RDT) . J. Clin. Oncol.30 ( Suppl. ), Abstract 7514 ( 2012 ).
   Google Scholar
• Mok T , TanE , ParkK . Randomized Phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC . J. Clin. Oncol.29 ( Suppl. ), Abstract TPS213 ( 2012 ).
   Google Scholar
• Scagliotti G , NovelloS , RamlauRet al. Results of the Phase 3 MARQUEE study: MET inhibitor tivantinib (ARQ 197) plus erlotinib vs erlotinib plus placebo in NSCLC . Proceedings of 17th ECCO–38th ESMO–32nd ESTRO European Cancer Congress ( 2013 ) ( Abstract E17-1821 ).
   Google Scholar
• Scagliotti GV , NovelloS , SchillerJHet al. Rationale and design of MARQUEE: a Phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer . Clin. Lung Cancer13 ( 5 ), 391 – 395 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Shaw AT , KimDW , NakagawaKet al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer . N. Engl. J. Med.368 ( 25 ), 2385 – 2394 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Davidenko I , IvensonT , DonehowerRC , TjulandinS , DeptalaA . Updated efficacy, biomarker, and exposure–response data from a Phase 2 study of rilotumumab plus epirubicin, cisplatin, and capecitabine in gastric or esophagogastric junction cancer . Presented at : European Society for Medical Oncology Congress , 28 September–2 October 2012 .
   Google Scholar
• Oliner KS , TangR , AndersonA , LanY , IvensonT . Evaluation of MET pathway biomarkers in a Phase 2 study of rilotumumab or placebo in combination with epirubicin/cisplatin/capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer . Presented at : Annual Meeting of the American Society of Clinical Oncology1–5 June 2012 .
   Google Scholar
• Oliner KS , TangR , AndersonAet al. Evaluation of MET pathway biomarkers in a Phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer . J. Clin. Oncol.30 ( Suppl. ), Abstract 4005 ( 2012 ).
   Google Scholar
• D’Arcangelo M , CappuzzoF . Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer . Biologics7 , 61 – 68 ( 2013 ).
   PubMedGoogle Scholar
• Tan E , ParkK , LimWTet al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC . J. Clin. Oncol.2011 ( Suppl. ), Abstract 7571 ( 2011 ).
   Google Scholar
• Maroun CR , RowlandsT . The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance . Pharmacol. Ther.142 ( 3 ), 316 – 338 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Spigel D , EdelmanM , O’ByrneKet al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal Phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial . J. Clin. Oncol.32 ( 5 Suppl. ) ( 2014 ).
   Google Scholar
• Eathiraj S , PalmaR , VolckovaEet al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 . J. Biol. Chem.286 ( 23 ), 20666 – 20676 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin Co Ltd announces discontinuation of Phase 3 clinical trial for ARQ 197 (Tivantinib) in combination with eroltinib in non-small-cell lung cancer patients . www.kyowa-kirin.com
   Google Scholar
• Yakes FM , ChenJ , TanJet al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth . Mol. Cancer Ther.10 ( 12 ), 2298 – 2308 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wakelee H , GettingerS , EngelmanJet al. A Phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC) . J. Clin. Oncol.28 ( Suppl. ), Abstract 3017 ( 2010 ).
   Google Scholar
• Gridelli C , PetersS , SgambatoA , CasaluceF , AdjeiAA , CiardielloF . ALK inhibitors in the treatment of advanced NSCLC . Cancer Treat Rev.40 ( 2 ), 300 – 306 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Abecasis GR , AutonA , BrooksLDet al. An integrated map of genetic variation from 1,092 human genomes . Nature491 ( 7422 ), 56 – 65 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cui JJ , Tran-DubeM , ShenHet al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) . J. Med. Chem.54 ( 18 ), 6342 – 6363 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kwak EL , CamidgeD , ClarkJet al. Clinical activity observed in a Phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 . J. Clin. Oncol.27 ( Suppl. 15 ), Abstract 3509 ( 2009 ).
   Web of Science ®Google Scholar
• Zou HY , LiQ , LeeJHet al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms . Cancer Res.67 ( 9 ), 4408 – 4417 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ou SH , KwakEL , Siwak-TappCet al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification . J. Thorac. Oncol.6 ( 5 ), 942 – 946 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chi AS , KwakE , ClarkJet al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma . J. Clin. Oncol.29 ( Suppl. ), Abstract 2072 ( 2011 ).
   Google Scholar
• Lennerz JK , KwakEL , AckermanAet al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib . J. Clin. Oncol.29 ( 36 ), 4803 – 4810 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Palma NA , AliSM , O’connorJet al. Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary . Case Rep. Oncol.7 ( 2 ), 503 – 508 ( 2014 ).
   PubMedGoogle Scholar
• Stein MN , HirshfieldKM , ZhongH , SingerEA , AliSM , GanesanS . Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib . Eur Urol. pii:S0302-2838(14)01020-3 ( 2014 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Qian F , EngstS , YamaguchiKet al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases . Cancer Res.69 ( 20 ), 8009 – 8016 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , VaishampayanU , RosenbergJEet al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma . J. Clin. Oncol.31 ( 2 ), 181 – 186 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Burbridge MF , BossardCJ , SaunierCet al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab . Mol. Cancer Ther.12 ( 9 ), 1749 – 1762 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shin JS , HongSW , MoonJHet al. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants . Invest. New Drugs32 ( 3 ), 389 – 399 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Janne PA , GrayN , SettlemanJ . Factors underlying sensitivity of cancers to small-molecule kinase inhibitors . Nat. Rev. Drug Discov.8 ( 9 ), 709 – 723 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• ISRCTN – ISRCTN00759419: Phase I dose-escalation study of S 49076 in patients with advanced solid tumors (13/01/2015) ( 2015 ). www.isrctn.com/ISRCTN00759419 .
   Google Scholar